Published

Question-based Drug Development for psilocybin.

No abstract is available for this record.

Open source BibTeX RIS

Bibliographic context

Journal: Unknown
Date: 2016-08-31
Source: Europe PMC
DOI: 10.1016/s2215-0366(16)30214-0
PubMed: 27568265

Authors

Dijkstra FM Jacobs GE Cohen AF.

Watch author

Topics and keywords

psilocybin Depression Other Hallucinogens Feasibility Studies Depression Psilocybin Drug Development

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Modeled Long-Term Effects of Psilocybin on Dynamic Activity and Effective Connectivity of Fronto-Striatal-Thalamic Circuits.Human Brain Mapping · 2026-06-30 Contribution of the Serotonin 5-HT2A Receptor to the Therapeutic Effect of Psilocin on Social Behavior Deficits in Mice Repeatedly Exposed to Social Defeat StressNeuropsychopharmacology Reports · 2026-08-31 Trajectories of psychedelic-assisted change: An observational study of a psilocybin retreat program followed by psychotherapeutic interventionsJournal of Psychedelic Studies · 2026-07-02 Past-Year Psilocybin and Alcohol Co-Use: Associations With Mental Health SymptomsJournal of Drug Issues · 2026-06-30 Study Protocol for "Exploring the safety and therapeutic potential of psilocybin in the treatment of anorexia nervosa in adolescents and young adults".PLoS ONE · 2026-06-29 Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit-Risk Considerations in Policy and Clinical DevelopmentUniversity of Groningen research database (University of Groningen / Centre for Information Technology) · 2026-06-28 Psilocybin reduces fear memory and restores neuroplasticity in the hippocampus and medial prefrontal cortex.Journal of Psychopharmacology · 2026-06-27 Blocking 5-HT2B receptors abolishes psilocybin’s efficacy in the rat forced swim testJournal of Psychopharmacology · 2026-06-22